Bellevue Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Bellevue Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-65,900	Closed	-$1.61M	–	221
2021 Q2	$1.61M	Hold	65,900	–	–	0.02%	144
2021 Q1	$1.7M	Buy	65,900 +21,000	+47%	+$924K	0.02%	145
2020 Q4	$2.4M	Hold	44,900	–	–	0.03%	143
2020 Q3	$1.85M	Hold	44,900	–	–	0.03%	145
2020 Q2	$2.18M	Buy	44,900 +2,900	+7%	+$139K	0.03%	133
2020 Q1	$1.77M	Buy	42,000 +2,000	+5%	+$82.4K	0.03%	133
2019 Q4	$1.71M	Sell	40,000 -50,400	-56%	-$2.19M	0.03%	134
2019 Q3	$3.25M	Sell	90,400 -13,400	-13%	-$406K	0.06%	120
2019 Q2	$2.77M	Hold	103,800	–	–	0.05%	121
2019 Q1	$2.79M	Buy	103,800 +8,000	+8%	+$187K	0.15%	96
2018 Q4	$1.55M	Buy	95,800 +38,800	+68%	+$753K	0.1%	101
2018 Q3	$1.18M	Buy	+57,000	New	+$897K	0.08%	122
2018 Q2	–	Sell	-34,550	Closed	-$776K	–	139
2018 Q1	$776K	Sell	34,550 -500	-1%	-$13.8K	0.08%	113
2017 Q4	$1.05M	Sell	35,050 -81,950	-70%	-$2.62M	0.11%	109
2017 Q3	$4.41M	Sell	117,000 -69,000	-37%	-$2.24M	0.46%	57
2017 Q2	$5.85M	Buy	186,000 +141,000	+313%	+$4.2M	0.69%	54
2017 Q1	$1.55M	Hold	45,000	–	–	0.21%	87
2016 Q4	$1.3M	Hold	45,000	–	–	0.27%	79
2016 Q3	$1.43M	Hold	45,000	–	–	0.26%	86
2016 Q2	$1.46M	Hold	45,000	–	–	0.27%	85
2016 Q1	$1.26M	Buy	+45,000	New	+$981K	0.23%	91

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group's ACAD Position: Q3 2021 in Review

Bellevue Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 65,900 shares — an estimated $1.61M sold.

Bellevue Group first reported a position in ACAD in Q1 2016 and held it in 21 quarters. The position peaked at $5.85M in Q2 2017. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

Bellevue Group reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bellevue Group sold 65,900 Acadia Pharmaceuticals shares in Q3 2021, an estimated $1.61M.
Bellevue Group first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 21 quarters.
Bellevue Group's Acadia Pharmaceuticals position peaked at $5.85M in Q2 2017.
237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.